A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Active:	Yes
Cancer Type:	Breast Cancer	NCT ID:	NCT04946864
Trial Phases:	Phase I Phase II	Protocol IDs:	APG2575XU103 (primary) NCI-2021-11630
Eligibility:	18 - 99 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Ascentage Pharma Group Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04946864

Summary

This is a multi-center, open-label, phase Ib/II study of APG-2575 as a single agent in
patients with advanced solid tumors or in combination with anti-cancer agents such as CDK 4/6
inhibitor palbociclib in patients with ER+/HER2- metastatic breast cancer (mBC) who have
progressed or relapsed after first line therapy

Objectives

The phase ?b is dose escalation of APG-2575 as a single agent or in combination with
palbociclib. A standard 3+3 design will be used to determine the MTD of APG-2575 as single
agent in patients with solid tumors and MTD and RP2D of APG-2575 in combination with
palbociclib in patients with breast cancer (MTD-combo). The phase II portion is a signal
seeking expansion of APG-2575 at RP2D in combination with palbociclib in patients with
ER+/HER2- metastatic breast cancers who have progressed during or relapsed after CDK
4/6inhibitor therapy. The phase ? portion will be conducted based on Simon's Minimax two
stage design.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.